Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | BCHE | P06276 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | JAK2 | O60674 | 1/20 | 0.72 |
| ▸ | HTR6 | P50406 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 7/20 | 0.67 |
| ▸ | DRD4 | P21917 | 7/20 | 0.67 |
| ▸ | DRD3 | P35462 | 7/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947433 | 0.94 | LMNA (0.76) | CYP2D6BCHELMNAHTTKDM4E | |
| SCHEMBL10463380 | 0.87 | LMNA (0.97) | CYP2D6BCHELMNAHTTKDM4E | |
| SCHEMBL1849016 | 0.87 | LMNA (0.90) | CYP2D6BCHELMNAHTTKDM4E | |
| SCHEMBL8789790 | 0.85 | LMNA (1.00) | CYP2D6BCHELMNAHTTKDM4E | |
| SCHEMBL762564 | 0.84 | HTR2A (0.78) | CYP2D6BCHELMNAHTTRAB9A | |
| SCHEMBL1856027 | 0.83 | BCHE (0.79) | CYP2D6BCHELMNAHTTKDM4E | |
| SCHEMBL948662 | 0.83 | HTR6 (1.00) | CYP2D6BCHELMNAHTTKDM4E | |
| SCHEMBL11838124 | 0.83 | BCHE (0.84) | CYP2D6BCHELMNAHTTKDM4E | |
| SCHEMBL1377300 | 0.82 | HTR1A (0.83) | DRD2DRD3SLC6A4HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL28260331 | 0.81 | HTR6 (0.97) | CYP2D6BCHELMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106794170-A | The active metabolite and two methanesulfonic acid dihydrate salts of active metabolite of [(piperazinyl of 4 methyl 1) methyl] the 1H indoles dimethanesulfonate monohydrates of 1 [(2 bromophenyl) sulfonyl] 5 methoxyl group 3 | 苏文生命科学有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9206186-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140005176-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| CN-101544592-B | Process for preparation of N-arylsulfonyl-3-substituted indoles | SUVEN LIFE SCIENCES LTD | 2013-08-21 | — | — | CN | disclosed |
| EP-1997495-B1 | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676843-A1 | Substituted indole ligands for the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2006-07-05 | — | — | EP | disclosed |
| EP-1648881-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GlaxoSmithKline S.p.A. (IT) | 2006-04-26 | — | — | EP | disclosed |
| CN-1720225-A | N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LTD (IN) | 2006-01-11 | — | — | CN | disclosed |
| EP-1608374-A1 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | Actimis Pharmaceuticals, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1581492-A1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | Suven Life Sciences Limited (IN) | 2005-10-05 | — | — | EP | disclosed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| WO-2005005411-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GLAXOSMITHKLINE S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004084898-A1 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004048330-A1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005176-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | CCR3, CCR2, CCR1 | CYP2D6 1499/4885BCHE 327/4885LMNA 4432/4885 |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | CYP2D6 1723/4885BCHE 3857/4885LMNA 655/4885 |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CYP2D6 1267/4885BCHE 1463/4885LMNA 922/4885 |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | CYP2D6 3612/4885BCHE 3144/4885LMNA 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.